Related Experiment Videos
Targeting of bladder cancer with monoclonal antibody NCRC48--a possible approach for intravesical therapy
R B Kunkler1, M C Bishop, D J Green
1Department of Urology, Nottingham City Hospital, UK.
Objective:
To determine the localization of the anti-MUC1 mucin monoclonal antibody (mAb) NCRC48 to bladder cancer following intravesical administration.
Patients And Methods:
mAb NCRC48 (330-500 micrograms) radiolabelled with 111indium (11-17 MBq) was administered intravesically to 12 unselected patients with radiological evidence of bladder cancer. Tumour localization was assessed by gamma-camera imaging and by tissue biodistribution studies on biopsies obtained at cystoscopy at about 2 or 24 h after the procedure. After 24 h, whole blood radioactivity was measured and 3 weeks after the procedure the serum level of human anti-mouse antibodies was estimated using an ELISA method.
Results:
Eleven patients had tumours confirmed at cystoscopy (grades 1-3, stages pTa-pT2). The mean uptake of NCRC48 by tumour and by normal urothelium (expressed as the percentage of the instilled dose/g x 10(3) +/- SD) at 2 h was 3.42 +/- 3.68 and 0.41 +/- 0.77 (P < 0.05). After 24 h, the values for tumour and normal urothelium were 1.17 +/- 1.18 and 0.17 +/- 0.11, respectively. Areas of increased activity on the scintigrams were consistent with the position of the tumours at cystoscopy. No radioactivity was detected in blood at 24 h and there was no evidence of a human anti-mouse antibody response.
Conclusion:
The MUC1 mucin may be a suitable antigen to study the potential of therapeutic strategies based on monoclonal antibody targeting of superficial bladder cancer and may allow the development of more effective agents in the treatment of this condition.
Insights
The anti-MUC1 monoclonal antibody NCRC48 effectively targets superficial bladder cancer. This study shows promising localization of NCRC48 to bladder tumors after intravesical administration, suggesting potential for new therapeutic strategies.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Superficial bladder cancer presents a significant clinical challenge.
- Targeted therapies are crucial for improving treatment efficacy.
- MUC1 mucin is a potential biomarker and therapeutic target in various cancers.
Purpose of the Study:
- To evaluate the intravesical administration and tumor localization of the anti-MUC1 monoclonal antibody (mAb) NCRC48 in patients with bladder cancer.
- To assess the biodistribution and potential immunogenicity of NCRC48 in this context.
Main Methods:
- Radiolabeled NCRC48 (anti-MUC1 mAb) was administered intravesically to 12 patients with bladder cancer.
- Tumor localization was assessed using gamma-camera imaging and tissue biodistribution studies.
- Blood radioactivity and human anti-mouse antibody response were monitored.
Main Results:
- NCRC48 demonstrated significant uptake in bladder tumors compared to normal urothelium at both 2 and 24 hours post-administration (P < 0.05).
- Scintigraphy results correlated with cystoscopy findings, confirming tumor targeting.
- No detectable radioactivity was found in blood at 24 hours, and no anti-mouse antibody response was observed.
Conclusions:
- MUC1 mucin is a viable target for monoclonal antibody-based therapies in superficial bladder cancer.
- NCRC48 shows potential for developing targeted therapeutic strategies against bladder cancer.
- Intravesical administration of NCRC48 appears safe and effective for localized bladder cancer treatment.